Trulicity Cost in Oklahoma 2026: Cash Price, Medicaid, and Cheaper Alternatives

What Does Trulicity Actually Cost in Oklahoma Right Now?

The retail list price for Trulicity in Oklahoma is $931 per month in 2026, matching Eli Lilly's manufacturer list price. That figure covers a four-pen supply (one pen per week) at any dose strength. Because GLP-1 receptor agonists carry no generic equivalent yet, every Oklahoma pharmacy, from Walgreens in Tulsa to an independent pharmacy in Enid, quotes roughly the same cash number. [1]

Prices at specific Oklahoma retail chains in early 2026 are consistent with the national list price because dulaglutide has no FDA-approved generic. A GoodRx coupon at select Oklahoma locations may trim 5 to 15 percent from that figure depending on the pharmacy, though the final number still sits well above $800 per month for most patients paying without insurance. The absence of a generic matters: the FDA's Orange Book lists no approved bioequivalent for dulaglutide as of this writing.

Patients in Oklahoma City and Tulsa sometimes discover that mail-order pharmacy benefits through employer plans reduce their 90-day supply cost. That option depends entirely on the specific plan formulary, covered below. For patients with no insurance and no eligibility for manufacturer programs, the compounded route is the most direct path to a lower monthly spend, and it is addressed in a dedicated section.

Does Oklahoma Medicaid (SoonerCare) Cover Trulicity?

Oklahoma Medicaid, branded SoonerCare, does not cover Trulicity as of 2025. The Oklahoma Health Care Authority (OHCA) Preferred Drug List excludes dulaglutide from the covered GLP-1 class for type 2 diabetes at this time. [2]

This is a notable gap. Oklahoma has the 11th-highest adult obesity rate in the United States at 40.3%, according to CDC 2023 behavioral risk factor data [3], and the state ranks among the top ten for type 2 diabetes prevalence. Yet SoonerCare's formulary currently favors older agents such as metformin, sulfonylureas, and insulin for diabetes management. Some members may obtain Trulicity through an exception process if a prescriber documents medical necessity, but approval is not guaranteed and the prior authorization burden falls on the treating provider.

If you receive SoonerCare, talk with your prescriber about whether metformin or a covered SGLT-2 inhibitor could meet your glycemic targets while you pursue other cost options. Alternatively, the manufacturer access programs and 503A compounding route remain open to Medicaid patients who pay out of pocket.

Which Insurance Plans in Oklahoma Cover Trulicity?

Coverage depends on whether your plan is commercial, Medicare Part D, or Medicaid. Most large commercial carriers operating in Oklahoma, including Blue Cross Blue Shield of Oklahoma, Aetna, Cigna, and UnitedHealthcare, list Trulicity on Tier 3 of their formularies for a type 2 diabetes indication. [4] Tier 3 typically means a specialty copay of $80 to $150 per month after deductible, depending on your specific plan year and benefit design.

Medicare Part D plans cover dulaglutide for type 2 diabetes under standard formulary rules, though each plan's tier placement and cost-sharing differs. The Centers for Medicare and Medicaid Services cap out-of-pocket drug spending at $2,000 per year under the Inflation Reduction Act provisions beginning in 2025, which may meaningfully reduce annual spending for Oklahoma Medicare patients who take Trulicity throughout the year. [5]

A few practical steps for Oklahoma patients checking their own coverage:

• Call the member services number on the back of your insurance card and ask specifically whether NDC 00002-1433-80 (Trulicity 0.75 mg) or NDC 00002-1428-80 (1.5 mg) is covered.
• Ask whether a prior authorization is required and what clinical criteria apply (usually an A1C threshold and documented metformin trial).
• Request the specialty pharmacy list, because some Oklahoma plans require dispensing through an in-network specialty pharmacy rather than a retail chain.

How Does the Eli Lilly Savings Card Work in Oklahoma?

Commercially insured Oklahoma patients with no government coverage may enroll in the Lilly Insulin Value Program or the Trulicity Savings Card program to pay as little as $25 per month. The savings card is processed at the pharmacy point of sale and reduces cost-sharing on top of the commercial plan's benefit. [6]

The card does not work for patients covered by Medicare, Medicaid, or any federally funded program. Patients who attempt to use it on a government plan risk program termination and, in some cases, federal compliance issues. That restriction eliminates SoonerCare members and most Medicare Part D enrollees.

Enrollment takes about five minutes at LillyAnswers.com or via the Lilly Cares Foundation if income thresholds apply. Oklahoma patients who are uninsured and below 400% of the federal poverty level may qualify for free medication through the Lilly Cares patient assistance program rather than the savings card route.

Is Compounded Dulaglutide Legal in Oklahoma?

Yes. Compounded dulaglutide from an Oklahoma-licensed 503A pharmacy is currently legal for Oklahoma patients with a valid prescription from a licensed practitioner. [7]

The legal framework matters here. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed compounding pharmacies to prepare individualized prescriptions for specific patients when a prescriber determines the commercially available product does not meet a patient's needs. Dulaglutide is not currently on the FDA's 503B bulk drug list, and it has not been placed on the Category 1 or Category 2 lists that restrict 503A compounding. That means 503A pharmacies in Oklahoma may compound it legally as of this writing.

Two important caveats apply. First, FDA guidance on GLP-1 compounding has been evolving rapidly. The agency declared the commercial shortage of semaglutide over in early 2025, which triggered enforcement pressure on 503A semaglutide compounding. Dulaglutide's status could change if FDA takes a similar position. Second, compounded dulaglutide has not undergone the same bioequivalence testing as brand-name Trulicity. The clinical trial evidence described later in this article was generated with the Eli Lilly formulation.

Oklahoma patients considering compounded dulaglutide should confirm that their chosen pharmacy holds an active Oklahoma State Board of Pharmacy license and that the prescribing provider is Oklahoma-licensed. A telehealth provider can satisfy the prescribing requirement if the consultation meets Oklahoma telehealth standards.

What Does the Clinical Evidence Say About Dulaglutide?

Dulaglutide is a GLP-1 receptor agonist approved by the FDA on September 18, 2014. It mimics endogenous glucagon-like peptide-1, stimulating glucose-dependent insulin secretion, suppressing glucagon, and slowing gastric emptying. [8]

The REWIND trial (Researching Cardiovascular Events with a Weekly Incretin in Diabetes, N=9,901 patients across 24 countries) published in The Lancet in 2019 remains the cornerstone outcomes study. Participants had type 2 diabetes and either established cardiovascular disease or cardiovascular risk factors. Dulaglutide 1.5 mg once weekly produced a statistically significant 12% relative risk reduction in the primary composite endpoint of major adverse cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) compared with placebo over a median follow-up of 5.4 years (hazard ratio 0.88 to 95% CI 0.79 to 0.99, P = 0.026). [9]

The trial also found that dulaglutide reduced A1C by approximately 0.6 percentage points from a baseline mean of 7.3% and produced modest but sustained weight reduction of about 1.5 kg relative to placebo. Those numbers are more modest than the weight-loss figures seen with semaglutide 2.4 mg in STEP-1 (N=1,961 to 14.9% mean weight loss at 68 weeks vs. 2.4% placebo [10]), reflecting the fact that Trulicity is licensed for glycemic control and cardiovascular risk reduction, not as a weight-loss agent.

As the REWIND investigators wrote: "Dulaglutide should be considered for patients with type 2 diabetes who need additional cardiovascular protection beyond glycaemic control, particularly those who have not yet had a cardiovascular event." [9]

The FDA-approved label for Trulicity notes that the drug is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. [8]

What Are the Approved Doses and How Is It Administered?

Trulicity comes in four dose strengths: 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg. Each is packaged as a prefilled, single-dose autoinjector pen. Injection sites include the abdomen, thigh, or upper arm, rotated weekly. The pen does not require refrigeration for up to 14 days, which can be a practical advantage for Oklahoma patients with limited cooler access during summer travel.

The standard starting dose for most adults is 0.75 mg once weekly, titrated to 1.5 mg after four weeks if tolerated. The 3 mg and 4.5 mg doses are available for patients needing additional glycemic control. Dose escalation from 1.5 mg to 3 mg or from 3 mg to 4.5 mg requires at least four weeks at the lower dose first. [8]

Common side effects include nausea, diarrhea, vomiting, abdominal pain, and decreased appetite. These are most pronounced during the first four to eight weeks and typically attenuate with time. Trulicity carries a black-box warning for thyroid C-cell tumors observed in rodent studies; it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Can Oklahoma Patients Get Trulicity Through Telehealth?

Yes. Oklahoma state law permits telehealth prescribing of Trulicity when a valid prescriber-patient relationship is established, the provider holds an active Oklahoma medical license, and prescribing is clinically appropriate. [11]

Oklahoma joined the Interstate Medical Licensure Compact, which means providers licensed in other compact states may also see Oklahoma patients via telehealth. That has expanded access substantially in rural areas like the Panhandle, southeastern Oklahoma, and the Cimarron County region where endocrinologists are scarce.

A HealthRX provider licensed in Oklahoma can evaluate eligibility, review A1C, fasting glucose, weight, and cardiovascular risk factors, and issue a Trulicity prescription electronically to an Oklahoma pharmacy of the patient's choice, including mail-order pharmacies. The consultation typically takes 15 to 20 minutes.

What Is the Cheapest Way to Get Dulaglutide in Oklahoma in 2026?

The answer depends on your insurance status. This table summarizes the main pathways.

Pathway 1: Commercial insurance plus Eli Lilly savings card. Commercially insured patients who meet the savings card eligibility criteria may pay $25 per month. This is the lowest cost route for patients with private insurance.

Pathway 2: Lilly Cares patient assistance. Uninsured or underinsured patients below 400% of the federal poverty line ($60,240 for a single adult in 2025) may qualify for free medication directly from Eli Lilly. Applications go through LillyAnswers.com or 1-800-545-5979.

Pathway 3: Compounded dulaglutide from a 503A pharmacy. For patients who do not qualify for manufacturer programs and cannot afford $931 per month, a licensed Oklahoma 503A compounding pharmacy may fill a prescription at a substantially lower cost. Prices vary by pharmacy; typical ranges seen by HealthRX providers run from $100 to $250 per month depending on dose and supply, though patients should get a direct quote from any pharmacy they consider.

Pathway 4: GoodRx or similar coupon at retail. Coupon codes typically reduce the retail price to $820 to $870 at most Oklahoma locations. Still expensive, but meaningful for patients who need a bridge while insurance prior authorization is pending.

Pathway 5: Therapeutic substitution. If dulaglutide is unaffordable, a prescriber may consider whether semaglutide 0.5 mg or 1 mg (Ozempic) or another GLP-1 agent fits the clinical picture and carries better formulary positioning on a patient's specific plan. This is a clinical decision requiring provider input.

How Does Oklahoma's Diabetes Burden Affect Prescribing Patterns?

Oklahoma has a type 2 diabetes prevalence of 14.1% among adults, compared to the national average of 11.6%, according to CDC 2023 estimates. [3] The state's rural geography means many patients travel 60 or more miles to see an endocrinologist, making telehealth not just convenient but the only realistic access point for specialist-guided GLP-1 therapy in many counties.

The combination of high disease burden, low Medicaid coverage for newer agents, and rural access barriers creates a specific challenge for Oklahoma providers and patients. GLP-1 receptor agonists with cardiovascular outcome data, like dulaglutide, are guideline-recommended for high-risk patients by the American Diabetes Association 2024 Standards of Care, which state: "In patients with type 2 diabetes and established CVD or high/very high CVD risk, a GLP-1 receptor agonist with demonstrated CVD benefit should be initiated as part of the glucose-lowering regimen independent of A1C." [12]

That guideline language is direct. Oklahoma patients with diabetes and cardiovascular risk who cannot access Trulicity due to cost or formulary barriers may be missing a therapy that reduces their risk of heart attack and stroke by roughly 12% over five years.

SoonerCare Prior Authorization: What to Expect

Even though SoonerCare does not routinely cover Trulicity, providers can submit a prior authorization request arguing medical necessity. A successful appeal typically requires documentation of all the following:

• Current A1C measurement and the date of the test
• Documented failure or contraindication to at least two first-line agents (metformin plus a sulfonylurea or SGLT-2 inhibitor)
• Cardiovascular risk documentation (history of MI, stroke, documented atherosclerotic cardiovascular disease, or a 10-year ASCVD risk score above 10%)
• Prescriber attestation that brand-name Trulicity, rather than a covered alternative, is medically necessary

The OHCA medical policy review process can take 14 to 30 days. Patients who are approved receive coverage under the Medicaid fee schedule rather than the retail cash price, which can make a meaningful difference even if cost-sharing applies.

Storing Trulicity in Oklahoma's Climate

Oklahoma summers routinely exceed 100 degrees Fahrenheit. Trulicity pens must be refrigerated at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) until first use. After removal from the refrigerator, a single pen may be stored at room temperature below 86 degrees Fahrenheit (30 degrees Celsius) for up to 14 days. [8]

Leaving a pen in a car during an Oklahoma August, where interior temperatures routinely reach 140 degrees or more, will degrade the drug. Patients should carry an insulated medication case and avoid leaving pens in vehicles. If a pen has been exposed to temperatures above 86 degrees for an unknown period, it should not be used.